MRLB-223
MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis, Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53-independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl-expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eμ-myc lymphomas.MRLB-223 can be used for the research of Eμ-myc lymphoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 937727-03-2
- Formule: C23H23N5O3S
- Masse moléculaire:449.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
|
HDAC1 |
HDAC2 |
HSP90 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | GI50 |
97 nM
Compound: 2
|
Growth inhibition of human HCT116 cells after 96 hrs
Growth inhibition of human HCT116 cells after 96 hrs
|
[PMID: 24900838] |
| HCT-116 | IC50 |
400 nM
Compound: 2
|
Inhibition of HDAC in human HCT116 cells assessed as plasma drug level causing increase in H2BK5 acetylation after 24 hrs by ELISA
Inhibition of HDAC in human HCT116 cells assessed as plasma drug level causing increase in H2BK5 acetylation after 24 hrs by ELISA
|
[PMID: 24900838] |
| HEK293 | IC50 |
>30 μM
Compound: 2
|
Inhibition of human ERG expressed in HEK cells by voltage clamp assay
Inhibition of human ERG expressed in HEK cells by voltage clamp assay
|
[PMID: 24900838] |
| HEL | GI50 |
120 nM
Compound: 2
|
Growth inhibition of HEL cells after 96 hrs
Growth inhibition of HEL cells after 96 hrs
|
[PMID: 24900838] |
| Jurkat | GI50 |
110 nM
Compound: 2
|
Growth inhibition of human Jurkat cells after 96 hrs
Growth inhibition of human Jurkat cells after 96 hrs
|
[PMID: 24900838] |
| Sf9 | IC50 |
45 nM
Compound: 2
|
Inhibition of FLAG-tagged full-length human recombinant HDAC2 expressed in baculovirus infected Sf9 cells using acetyl-lysine containing peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by fluorescence as
Inhibition of FLAG-tagged full-length human recombinant HDAC2 expressed in baculovirus infected Sf9 cells using acetyl-lysine containing peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by fluorescence as
|
[PMID: 24900838] |
In Vitro
MRLB-223 (0.2-10 μM; 24-48 h) induces concentration-dependent apoptosis in Eμ-myc lymphoma cells via the intrinsic apoptotic pathway with delayed kinetics, with an IC70 of 5 μM at 24 hours and 0.5 μM at 48 hours[1].
MRLB-223 (0-12 μM; 24 h) induces concentration-dependent apoptosis in Eμ-myc and Eμ-myc/p53-/- lymphoma cells independently of p53, while overexpression of Bcl-2 blocks this apoptotic effect[1].
MRLB-223 (0-30 μM; 24-72 h) induces concentration-dependent cell death in FDCP-1 mouse myeloid cells with delayed kinetics, requiring longer incubation times for maximal effect[1].
MRLB-223 (0-26 μM; 72 h) induces concentration-dependent cell death in FDCP-1/Bcr-Abl and FDCP-1/Bcr-AblT315I cells with delayed kinetics, and Bcr-Abl degradation occurs as a downstream consequence of caspase-mediated apoptosis[1].
MRLB-223 (10 μM; 24 h) induces hyperacetylation of Hsp90 in FDCP-1/Bcr-Abl cells despite lacking activity against HDAC6[1].
MRLB-223 (0-16 μM; 72 h) induces concentration-dependent cell death in FDCP-1/Bcr-Abl cells, and knockdown of HDAC6 does not enhance this apoptotic effect[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Eμ-myc, Eμ-myc/p53-/-, and Eμ-myc/Bcl-2 lymphoma cells
-
Concentration:0-12 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent PI uptake in Eμ-myc and Eμ-myc/p53-/- cells, with both cell lines showing similar sensitivity.
Suppressed MRLB-223-mediated tumor cell death was observed when Bcl-2 was overexpressed.
-
Cell Line:FDCP-1/Bcr-Abl and FDCP-1/Bcr-Abl(T315I) mouse myeloid cells
-
Concentration:0-26 μM (72 h PI uptake assay); 5, 10 μM (48 h Bcr-Abl degradation assay)
-
Incubation Time:72 h (PI uptake assay); 48 h (Bcr-Abl degradation assay)
-
Result:Induced concentration-dependent PI uptake in FDCP-1/Bcr-Abl and FDCP-1/Bcr-Abl(T315I) cells at 72 hours, with both cell lines showing equivalent sensitivity.
Induced Bcr-Abl degradation concomitant with apoptosis in cells treated with 5 or 10 μM for 48 hours.
Suppressed apoptosis and maintained Bcr-Abl expression when co-treated with the caspase inhibitor Q-VD-OPh for 48 hours.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (6- to 8-week-old; injected intravenously with 5×105 Eμ-myc lymphoma cells)[1]
-
Dosage:15 mg/kg (therapy studies; in vivo apoptosis assays; FDG-PET analysis)
-
Administration:i.p.; daily, continuous (therapy studies); single dose (in vivo apoptosis assays; FDG-PET analysis)
-
Result:Reduced average peripheral white blood cell counts to 23.9×103/μL by day 21 and 33.8×103/μL by day 35 (vehicle controls reached 39.2×103/μL by day 21).
Increased median mouse survival to 42 days (vehicle controls had 33 days).
Induced delayed histone H3 and H4 hyperacetylation in lymphoma cells, with minimal acetylation at 2 hours post-dose and gradual increases over time.
Showed no reduction in lymph node FDG uptake at 4 hours post-dose, but a decrease was observed by 48 hours post-dose.
Chemical Information
-
CAS No. 937727-03-2
-
Masse moléculaire 449.53
-
Formule C23H23N5O3S
-
SMILES
O=C1OC2(CCN(CC2)C3=NC=C(C(NC4=C(N)C=CC(C5=CC=CS5)=C4)=O)C=C3)CN1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)